Variability in platelet responsiveness to clopidogrel among 544 individuals

Victor L. Serebruany, Steven R. Steinhubl, Peter B. Berger, Alex I. Malinin, Deepak L. Bhatt, Eric J. Topol

Research output: Contribution to journalArticle

Abstract

We sought to describe the responses of patients to clopidogrel using ex vivo measures of platelet aggregation and activation in a large, heterogeneous population. Recently, a number of reports, using various definitions, have dichotomized patients who are treated with clopidogrel into a minority of "non-responders" and a majority of "responders." Such classifications imply that treatment leads to an all-or-none response, with potentially important clinical implications. We conducted secondary post-hoc analyses of a dataset consisting of volunteers (n = 94) and patients after coronary stenting (n = 405), with heart failure (n = 25), and after stroke (n = 20). The response of subjects to clopidogrel followed a normal, bell-shaped distribution, with a mean and standard deviation of 41.9 ± 20.8% when aggregation was induced by 5 μmol/l of adenosine diphosphate. When hyporesponsiveness and hyper-responsiveness to clopidogrel were considered to be two standard deviations less than and greater than the mean, respectively, the prevalence of hyporesponsiveness and hyper-responsiveness in these patients was 4.2% and 4.8%, respectively. Pretreatment platelet activity and clinical characteristics were not associated with responsiveness to clopidogrel. Individuals receiving clopidogrel exhibit a wide variability in response that follows a normal distribution. The clinical implications of this variability are unknown but potentially are important. Clinical trials are needed to define whether hyporesponders to clopidogrel are at increased risk for thrombotic events and whether hyper-responders are at increased risk for bleeding. If so, the individualization of antiplatelet therapy, including clopidogrel dosing, may be possible in the future but will require the ability to easily and reproducibly measure responsiveness by a method that has been proven to be predictive of clinical events.

Original languageEnglish (US)
Pages (from-to)246-251
Number of pages6
JournalJournal of the American College of Cardiology
Volume45
Issue number2
DOIs
StatePublished - Jan 18 2005
Externally publishedYes

Fingerprint

clopidogrel
Blood Platelets
Normal Distribution
Platelet Activation
Platelet Aggregation
Adenosine Diphosphate

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Serebruany, V. L., Steinhubl, S. R., Berger, P. B., Malinin, A. I., Bhatt, D. L., & Topol, E. J. (2005). Variability in platelet responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology, 45(2), 246-251. https://doi.org/10.1016/j.jacc.2004.09.067

Variability in platelet responsiveness to clopidogrel among 544 individuals. / Serebruany, Victor L.; Steinhubl, Steven R.; Berger, Peter B.; Malinin, Alex I.; Bhatt, Deepak L.; Topol, Eric J.

In: Journal of the American College of Cardiology, Vol. 45, No. 2, 18.01.2005, p. 246-251.

Research output: Contribution to journalArticle

Serebruany, VL, Steinhubl, SR, Berger, PB, Malinin, AI, Bhatt, DL & Topol, EJ 2005, 'Variability in platelet responsiveness to clopidogrel among 544 individuals', Journal of the American College of Cardiology, vol. 45, no. 2, pp. 246-251. https://doi.org/10.1016/j.jacc.2004.09.067
Serebruany, Victor L. ; Steinhubl, Steven R. ; Berger, Peter B. ; Malinin, Alex I. ; Bhatt, Deepak L. ; Topol, Eric J. / Variability in platelet responsiveness to clopidogrel among 544 individuals. In: Journal of the American College of Cardiology. 2005 ; Vol. 45, No. 2. pp. 246-251.
@article{ad182a58bb884b7486189c94dcc65fca,
title = "Variability in platelet responsiveness to clopidogrel among 544 individuals",
abstract = "We sought to describe the responses of patients to clopidogrel using ex vivo measures of platelet aggregation and activation in a large, heterogeneous population. Recently, a number of reports, using various definitions, have dichotomized patients who are treated with clopidogrel into a minority of {"}non-responders{"} and a majority of {"}responders.{"} Such classifications imply that treatment leads to an all-or-none response, with potentially important clinical implications. We conducted secondary post-hoc analyses of a dataset consisting of volunteers (n = 94) and patients after coronary stenting (n = 405), with heart failure (n = 25), and after stroke (n = 20). The response of subjects to clopidogrel followed a normal, bell-shaped distribution, with a mean and standard deviation of 41.9 ± 20.8{\%} when aggregation was induced by 5 μmol/l of adenosine diphosphate. When hyporesponsiveness and hyper-responsiveness to clopidogrel were considered to be two standard deviations less than and greater than the mean, respectively, the prevalence of hyporesponsiveness and hyper-responsiveness in these patients was 4.2{\%} and 4.8{\%}, respectively. Pretreatment platelet activity and clinical characteristics were not associated with responsiveness to clopidogrel. Individuals receiving clopidogrel exhibit a wide variability in response that follows a normal distribution. The clinical implications of this variability are unknown but potentially are important. Clinical trials are needed to define whether hyporesponders to clopidogrel are at increased risk for thrombotic events and whether hyper-responders are at increased risk for bleeding. If so, the individualization of antiplatelet therapy, including clopidogrel dosing, may be possible in the future but will require the ability to easily and reproducibly measure responsiveness by a method that has been proven to be predictive of clinical events.",
author = "Serebruany, {Victor L.} and Steinhubl, {Steven R.} and Berger, {Peter B.} and Malinin, {Alex I.} and Bhatt, {Deepak L.} and Topol, {Eric J.}",
year = "2005",
month = "1",
day = "18",
doi = "10.1016/j.jacc.2004.09.067",
language = "English (US)",
volume = "45",
pages = "246--251",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Variability in platelet responsiveness to clopidogrel among 544 individuals

AU - Serebruany, Victor L.

AU - Steinhubl, Steven R.

AU - Berger, Peter B.

AU - Malinin, Alex I.

AU - Bhatt, Deepak L.

AU - Topol, Eric J.

PY - 2005/1/18

Y1 - 2005/1/18

N2 - We sought to describe the responses of patients to clopidogrel using ex vivo measures of platelet aggregation and activation in a large, heterogeneous population. Recently, a number of reports, using various definitions, have dichotomized patients who are treated with clopidogrel into a minority of "non-responders" and a majority of "responders." Such classifications imply that treatment leads to an all-or-none response, with potentially important clinical implications. We conducted secondary post-hoc analyses of a dataset consisting of volunteers (n = 94) and patients after coronary stenting (n = 405), with heart failure (n = 25), and after stroke (n = 20). The response of subjects to clopidogrel followed a normal, bell-shaped distribution, with a mean and standard deviation of 41.9 ± 20.8% when aggregation was induced by 5 μmol/l of adenosine diphosphate. When hyporesponsiveness and hyper-responsiveness to clopidogrel were considered to be two standard deviations less than and greater than the mean, respectively, the prevalence of hyporesponsiveness and hyper-responsiveness in these patients was 4.2% and 4.8%, respectively. Pretreatment platelet activity and clinical characteristics were not associated with responsiveness to clopidogrel. Individuals receiving clopidogrel exhibit a wide variability in response that follows a normal distribution. The clinical implications of this variability are unknown but potentially are important. Clinical trials are needed to define whether hyporesponders to clopidogrel are at increased risk for thrombotic events and whether hyper-responders are at increased risk for bleeding. If so, the individualization of antiplatelet therapy, including clopidogrel dosing, may be possible in the future but will require the ability to easily and reproducibly measure responsiveness by a method that has been proven to be predictive of clinical events.

AB - We sought to describe the responses of patients to clopidogrel using ex vivo measures of platelet aggregation and activation in a large, heterogeneous population. Recently, a number of reports, using various definitions, have dichotomized patients who are treated with clopidogrel into a minority of "non-responders" and a majority of "responders." Such classifications imply that treatment leads to an all-or-none response, with potentially important clinical implications. We conducted secondary post-hoc analyses of a dataset consisting of volunteers (n = 94) and patients after coronary stenting (n = 405), with heart failure (n = 25), and after stroke (n = 20). The response of subjects to clopidogrel followed a normal, bell-shaped distribution, with a mean and standard deviation of 41.9 ± 20.8% when aggregation was induced by 5 μmol/l of adenosine diphosphate. When hyporesponsiveness and hyper-responsiveness to clopidogrel were considered to be two standard deviations less than and greater than the mean, respectively, the prevalence of hyporesponsiveness and hyper-responsiveness in these patients was 4.2% and 4.8%, respectively. Pretreatment platelet activity and clinical characteristics were not associated with responsiveness to clopidogrel. Individuals receiving clopidogrel exhibit a wide variability in response that follows a normal distribution. The clinical implications of this variability are unknown but potentially are important. Clinical trials are needed to define whether hyporesponders to clopidogrel are at increased risk for thrombotic events and whether hyper-responders are at increased risk for bleeding. If so, the individualization of antiplatelet therapy, including clopidogrel dosing, may be possible in the future but will require the ability to easily and reproducibly measure responsiveness by a method that has been proven to be predictive of clinical events.

UR - http://www.scopus.com/inward/record.url?scp=11844256436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844256436&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2004.09.067

DO - 10.1016/j.jacc.2004.09.067

M3 - Article

C2 - 15653023

AN - SCOPUS:11844256436

VL - 45

SP - 246

EP - 251

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -